FinancialContent is the trusted provider of stock market information to the media industry.
April 24, 2012 at 08:20 AM EDT
Pharmaceutical Companies Look to Biotech Industry to Combat Losses from Expiring Patents
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Keryx Biopharmaceuticals

NEW YORK, NY -- (Marketwire) -- 04/24/12 -- Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations for its pharmaceutical products between 2009 and 2013. It is apparent that pharmaceutical companies have begun to make strategic decisions to combat the anticipated losses. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Achillion Pharmaceuticals (NASDAQ: ACHN) and Keryx Biopharmaceuticals (NASDAQ: KERX).

Access to full reports can be found at:

www.ParagonReport.com/ACHN

www.ParagonReport.com/KERX

According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. As larger companies continue to reduce spending on research and development they continue to look at smaller biotech companies to diversify their product lines. Mergers & Acquisitions allows bigger companies to acquire products and technologies that are already proven in the market place, avoiding the many risks associated with research and development.

On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.

Keryx Biopharmaceuticals recently announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis. This study is part of an ongoing Phase 3 program for ferric citrate in Japan for the treatment of hyperphosphatemia.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More